icon-    folder.gif   Conference Reports for NATAP  
  IAS 2017: Conference on HIV Pathogenesis
Treatment and Prevention
Paris, France
July 23-26 2017
Back grey_arrow_rt.gif
Prevalence over time and predictive factors of HIV-associated
neurocognitive disorder (HAND) in HIV-positive patients

  Download the PDF here
Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
I. Mastrorosa, C. Pinnetti, P. Lorenzini, P. Balestra, R. Libertone, M. Ricottini, S. Menichetti, M.M. Plazzi, V. Mazzotta, M. Zaccarelli, A. Ammassari, A. Antinori National Institute for Infectious Diseases “Lazzaro Spallanzani”, I.R.C.C.S., Rome, Italy







1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69:1789-1799.
2. Bhaskaran K et al. CASCADE collaboration. Changes in the incidence and predictors of human immunodeficiency virus associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008; Feb;63(2):213-21
3. Heaton RK et al., for the CHARTER Group, HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy : CHARTER Study. Neurology 2010;75;2087
4. Heaton RK et al., for the CHARTER and HNRC Groups. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J. Neurovirol 2011; 17:3-16
5. Heaton RK. et al., for the CHARTER Group. Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study. Clin Inf Dis 2015; 60(3):473-80
6. Haddow LJ et al. for the CIPHER Study Group, Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients. AIDS Behav 2017 [Epub ahead of print]